2020 SITC Cancer Immunotherapy Winter School Schedule

The following is the schedule for the 2020 SITC Cancer Immunotherapy Winter School, taking place Jan. 13–17, 2020 in Houston.

5-Day Program
Days 1 & 2 (Jan. 13–14, 2020) – Basic tumor immunology and cancer immunotherapy topics

Days 3, 4, & 5 (Jan. 15–17, 2020) – In-depth topics with multi-track structure

Return to ...

SITC WINTER SCHOOL HOME

Schedule

Monday, Jan. 13, 2020

8:00 – 8:30 a.m.	Registration and Breakfast
8:30 – 9:00 a.m.	Welcome
9:00 – 10:00 a.m.	Immunotherapy Overview: History of the Field Michael T. Lotze, MD – University of Pittsburgh
10:00 – 10:10 a.m.	Break
10:10 – 11:10 a.m.	Innate Immunity: Cellular Mechanisms and Signaling Lewis Lanier, PhD – University of California San Francisco
11:10 a.m. – 12:10 p.m.	Adaptive Immunity: Cellular Mechanisms and Signaling Olivera Finn, PhD – University of Pittsburgh
12:10 – 1:00 p.m.	Lunch - Roundtables with Faculty
1:00 – 2:00 p.m.	Tumor Biology: Cellular Mechanisms and Signaling Francesco Marincola, MD, FACS – Refuge Consulting
2:00 – 3:00 p.m.	Tumor Immunosuppression Mechanisms Gregory M. Delgoffe, PhD – University of Pittsburgh
3:00 – 3:15 p.m.	Break
3:15 – 4:15 p.m.	Tumor Microenvironment: Complexity of Cells and Molecules Regulating Intratumoral Immunity Victor H. Engelhard, PhD – University of Virginia School of Medicine
4:15 – 5:15 p.m.	Antigen Presentation Olivera Finn, PhD – University of Pittsburgh	T Cell Exhaustion Gregory M. Delgoffe, PhD – University of Pittsburgh	Innate Immune Mechanisms Dendritic Cells and NK Cells Lewis Lanier, PhD– University of California San Francisco

Tuesday, Jan. 14, 2020

8:30 – 8:55 a.m.	Registration/Breakfast
8:55 – 9:00 a.m.	Welcome Back
9:00 – 10:00 a.m.	Immunotherapeutic Strategy: Immune Checkpoint Blockade Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
10:00 – 10:10 a.m.	Break
10:10 – 11:10 a.m.	Immunotherapeutic Strategy: Adoptive Cell and CAR T Therapies Catherine Bollard, MD – Baylor College of Medicine
11:10 a.m. – 12:10 p.m.	Presenting Your Data in Talks and Manuscripts Jennifer Wargo MD MMSc – The University of Texas MD Anderson Cancer Center
12:10 – 1:00 p.m.	Lunch Roundtables
1:00 – 2:00 p.m.	Intratumoral and Local Therapy Howard L. Kaufman, MD, FACS – Replimune Group Inc.
2:00 – 3:00 p.m.	Immunity and Therapeutic Efficacy Jerome Galon, PhD – Universite Pierre Et Marie Curie, Sorbonne Universites
3:00 – 3:15 p.m.	Break
3:15 – 4:15 p.m.	Cytokine-based Immunotherapies and Other Molecular Bispecifics, Other Immunotherapies Michael T. Lotze, MD – University of Pittsburgh	T Cell Agonists Andrew Weinberg, PhD – Earle A. Chiles Research Institute	The Microbiome and Immunotherapy Jennifer Wargo MD MMSc – The University of Texas MD Anderson Cancer Center
4:30 – 6:00 p.m.	Welcome Reception

Wednesday, Jan. 15, 2020

8:00 – 8:25 a.m.	Registration/Breakfast
8:25 – 8:30 a.m.	Welcome Back
8:30 – 9:30 a.m.	Immunotherapeutic Strategy: Can Cancer Vaccines Really Work? Lisa H. Butterfield, PhD – The Parker Institute for Cancer Immunotherapy/University of California San Francisco
9:30 – 10:30 a.m.	Data and Statistical Analyses: Analyzing Basic and High Throughput Nikesh Kotecha, PhD – The Parker Institute for Cancer Immunotherapy
10:30 – 10:40 a.m.	Break
10:40 – 11:40 a.m.	Researchers' Track– Antigen Identification Victor H. Engelhard, PhD – University of Virginia School of Medicine	Clinicians' Track– Phase I Immunotherapy Clinical Trials Howard L. Kaufman, MD, FACS – Replimune Group Inc.
11:40 a.m. – 12:30 p.m.	Lunch Roundtables
12:30 – 1:30 p.m.	Researchers' Track – Pre-Clinical Animal Models Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine	Clinicians' Track – Phase II and III Immunotherapy Clinical Trials Daniel P. Normolle, PhD – University of Pittsburgh
1:30 – 2:30 p.m.	Researchers' Track – Clinical Trial Basics De-Coded Leisha A. Emens, MD, PhD - UPMC Hilllman Cancer Center	Clinicians' Track – How to Get a Predictive Biomarker out of Every Clinical Trial Lisa H. Butterfield, PhD – PICI Research Center, Parker Institute for Cancer Immunotherapy; University of California, San Francisco
2:30 – 2:45 p.m.	Break

2:45 – 3:45 p.m.

Deep TCR and BCR Sequencing as a Biomarker for Cancer
Sacha Gnjatic, PhD – Ichan School of Medicine at Mount Sinai

Industry-Led Session: New Agents
Ginna G. Laport, MD – Tempest Therapeutics

Patient Considerations that Impact Treatment & Clinical Trials
Deborah Collyar - Patient Advocates in Research

Thursday, Jan. 16, 2020

8:00 – 8:25 a.m.	Registration/Breakfast
8:25 – 8:30 a.m.	Welcome Back
8:30 – 9:30 a.m.	Grantsmanship Christian Capitini, MD – University of Wisconsin-Madison
9:30 – 9:40 a.m.	Break
9:40 – 10:40 a.m.	Researchers' Track – Tumor Cell Analyses (Pathology) Jerome Galon, PhD – Universite Pierre Et Marie Curie, Sorbonne Universites	Clinicians' Track – Autoimmunity and irAEs Michael A. Morse, MD – Duke University Medical Center
10:40 – 11:40 a.m.	Researchers' Track – Applications of Computational Biology/Machine Learning to Immuno-Oncology Takis Benos, PhD—University of Pittsburgh	Clinicians' Track – Biomarker-Based Clinical Trials Jianda Yuan, MD, PhD – Merck
11:40 a.m. – 12:30 p.m.	Lunch Roundtables
12:30 – 1:30 p.m.	From Seamless Trial Designs to Seamless Indications in Oncology—Regulatory Considerations for Tissue Agnostic Drug Development Marc Theoret – U.S. Food and Drug Administration
1:30 – 2:30 p.m.	Researchers' Track – Synthetic Immunology: Harnessing the Tools of Synthetic Biology to Engineer Next-Generation Cell Therapies Kole Roybal, PhD – University of California, San Francisco	Clinicians' Track – Immunotherapy in Special Patient Populations Michael A. Morse, MD – Duke University Medical Center
2:30 – 3:30 p.m.	Researchers' Track – Pre-Clinical Combination Immunotherapy Karolina Palucka, MD, PhD—The Jackson Laboratory for Genomic Medicine	Clinicians' Track – Clinical Endpoints Michael A. Morse, MD – Duke University Medical Center
3:30 – 3:45 p.m.	Break

3:45 – 4:45 p.m.

Hands On Dataset Analysis (Bring Your Own Datasets)
Takis Benos, PhD – University of Pittsburgh

Development of a Translational Idea
Francesco Marincola, MD, FACS – Refuge Consulting

Methods to Assess and Discover Biomarkers
Jianda Yuan, MD, PhD – Merck

Friday, Jan. 17, 2020

8:00 – 8:25 a.m.	Registration/Breakfast
8:25 – 8:30 a.m.	Welcome Back
8:30 – 9:30 a.m.	Cancer Immunotherapy: An FDA Perspective Raj Puri, MD, PhD, FDA, CBER – U.S. Food and Drug Administration
9:30 – 10:30 a.m.	GMP: It’s Not Science, It’s Manufacturing Lisa H. Butterfield, PhD – The Parker Institute for Cancer Immunotherapy/University of California San Francisco
10:30 – 10:40 a.m.	Break
10:40 – 11:40 a.m.	Researchers' – Track How to Handle Big Data and High-Throughput Data Nikesh Kotecha, PhD – The Parker Institute for Cancer Immunotherapy	Clinicians' Track – Combination Immunotherapies Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center
11:40 a.m. – 12:30 p.m.	Lunch Roundtables
12:30 – 1:30 p.m.	Researchers' Track – Preclinical Safety/Efficacy	Clinicians' Track – Patient Monitoring/ Education Deborah Collyar – Patient Advocates in Research

1:30 – 2:30 p.m.	Career Development Awards Christian Capitini, MD – University of Wisconsin-Madison	Careers in Industry Ginna Laport, MD – Tempest Therapeutics	Careers in Government Raj Puri, MD, PhD, FDA, CBER – U.S. Food and Drug Administration
2:30 – 2:40 p.m.	Break
2:40 – 3:40 p.m.	Perspective on Direction of the Field Christian Capitini, MD – University of Wisconsin - Carbone Cancer Center
3:40 – 3:50 p.m.	Closing